Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty-three analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one […]
More Stories
Merit Medical Systems, Inc. (NASDAQ:MMSI) Shares Acquired by Ameriprise Financial Inc.
Ameriprise Financial Inc. lifted its position in Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) by 3.7% in the 4th...
Algert Global LLC Acquires New Position in Inseego Corp. (NASDAQ:INSG)
Algert Global LLC acquired a new position in shares of Inseego Corp. (NASDAQ:INSG – Free Report) during the 4th quarter,...
Ameriprise Financial Inc. Increases Position in The Toro Company (NYSE:TTC)
Ameriprise Financial Inc. boosted its holdings in The Toro Company (NYSE:TTC – Free Report) by 172.9% in the fourth quarter,...
Ameriprise Financial Inc. Sells 22,808 Shares of Equifax Inc. (NYSE:EFX)
Ameriprise Financial Inc. reduced its stake in shares of Equifax Inc. (NYSE:EFX – Free Report) by 16.4% during the 4th...
Ameriprise Financial Inc. Lowers Holdings in Clear Secure, Inc. (NYSE:YOU)
Ameriprise Financial Inc. reduced its stake in shares of Clear Secure, Inc. (NYSE:YOU – Free Report) by 11.8% during the...
Ameriprise Financial Inc. Purchases 13,501 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
Ameriprise Financial Inc. raised its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 4.2% in the 4th quarter,...